Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

NCT00925600 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00925600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00925600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2009
Completion date
May 12, 2016
Enrollment
769 (actual)
Sites
172

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, cataract, low bone mineral density, osteopenia, osteoporosis, prostate cancer